Treatment Adjustment for Elevated Androstenedione with Low Testosterone in Adult CAH
Yes, you need to increase the glucocorticoid dose when androstenedione is elevated, as this indicates inadequate disease control regardless of the testosterone level. In adult males with CAH, testosterone primarily reflects gonadal (testicular) function rather than adrenal androgen production, making it unreliable for monitoring therapy adequacy 1.
Why Testosterone is Misleading in This Context
The low testosterone you're observing likely reflects suppressed gonadal function rather than adequate disease control. This can occur from:
- Testicular adrenal rest tumors (TART) causing Leydig cell dysfunction - found in 44% of adult men with classic CAH 2
- Altered gonadotropin secretion from chronic androgen excess 1
- The testosterone being measured is gonadal, not adrenal in origin
The Key Monitoring Parameter
Androstenedione is your primary marker for treatment adequacy in adults 1. When elevated, it signals:
- Inadequate suppression of adrenal androgen production
- Need for glucocorticoid dose adjustment
- Risk of ongoing virilization and metabolic complications
Recommended Treatment Adjustment
Increase the glucocorticoid dose incrementally while monitoring for signs of overtreatment 1. For adults, typical maintenance ranges are:
- Hydrocortisone: 15-25 mg/day in 2-3 divided doses
- Prednisone: 5-7.5 mg/day in 2 divided doses
- Prednisolone: 4-6 mg/day in 2 divided doses
- Dexamethasone: 0.25-0.5 mg/day once daily
Critical Caveat About Dexamethasone
While dexamethasone effectively suppresses androgens, it carries significantly higher risk of insulin resistance and metabolic complications compared to hydrocortisone or prednisolone 3. If your patient is on dexamethasone, consider switching to a shorter-acting glucocorticoid rather than increasing the dexamethasone dose.
Additional Monitoring Needed
Beyond adjusting the dose, you should:
- Screen for TART with testicular ultrasound - the low testosterone may indicate Leydig cell damage requiring additional management 1, 2
- Check 17-hydroxyprogesterone levels - though optimal targets aren't well-defined, this provides additional disease control information 1
- Monitor for glucocorticoid excess: blood pressure, weight gain, glucose metabolism, bone density 1, 2
- Assess mineralocorticoid adequacy: plasma renin activity, blood pressure, electrolytes 1
The Balancing Act
The challenge is avoiding overtreatment (causing Cushingoid features, osteoporosis, insulin resistance) while achieving adequate androgen suppression 1, 3. Research shows that higher glucocorticoid doses correlate with increased blood pressure and insulin resistance, but inadequate dosing leads to poor disease control 3.
Attempting to completely normalize androstenedione typically results in overtreatment 1. The goal is reasonable suppression while minimizing glucocorticoid exposure - accept mildly elevated androstenedione rather than pushing doses into the supraphysiologic range.
Practical Algorithm
- Confirm inadequate control: Repeat androstenedione measurement (consider morning level)
- Increase glucocorticoid by 20-25% of current dose
- Recheck in 4-6 weeks: androstenedione, 17-OHP, blood pressure, weight
- Screen for TART if not done recently
- Titrate further if androstenedione remains significantly elevated, but watch for signs of overtreatment
- Consider switching agents if on dexamethasone or once-daily dosing
The low testosterone is a consequence of the disease process (likely TART or gonadotropin suppression), not an indicator that treatment is adequate. Focus on the androstenedione as your guide for glucocorticoid adjustment 1.